keytruda
MSD’s Keytruda shows promise in multiple myeloma
December 7, 2015Manufacturing and Production MSD, Revlimid, dexamethasone, keytruda, multiple myeloma, pembrolizumab
MSD has announced that it has initiated two Phase III studies based in part on the strength of early data, …
GSK and Merck to study immunotherapy combo in solid tumours
November 3, 2015Research and Development GSK, Merck, immunooncology, immunotherapy, keytruda, phase I
GSK and Merck will start a Phase I clinical trial in humans to evaluate GSK’s investigational cancer drugs with the …
Sales up at MSD while Keytruda hits survival target in late-stage trial
October 28, 2015Research and Development, Sales and Marketing MSD, Merck, financial results, keytruda, pembrolizumab
Worldwide sales at MSD were $10.1 billion in the third quarter of 2015, a 4% increase after accounting for the …
MSD’s Keytruda receives green light from NICE for NHS use
October 12, 2015Sales and Marketing MSD, Merck, NICE, keytruda, melanoma, pembrolizumab, skin cancer
The UK healthcare watchdog NICE has recommended Keytruda as a treatment for advanced skin cancer – its second endorsement of …
NICE approves Merck’s Keytruda for advanced skin cancer following ipilimumab treatment
October 7, 2015Research and Development Merck, NHS, NICE, keytruda, skin cancer
The National Institute for Health and Care Excellence (NICE) has approved Merck’s Keytruda (pembrolizumab) for treating advanced skin cancer after …
FDA approves Merck’s Keytruda for advanced NSC lung cancer
October 5, 2015Research and Development, Sales and Marketing BMS, NSCL, keytruda, lung cancer, merck sharp and dohme, opdivo
The US Food and Drug Administration has granted accelerated approval for Merck’s Keytruda (pembrolizumab) to treat patients with advanced (metastatic) …
Lung cancer market to hit $10.9bn by 2021
September 10, 2015Sales and Marketing AZD9291, GBI Research, GlobalData, NSCLC, industry analysis, industry intelligence, industry reports, keytruda, market intelligence lung cancer, market reports, market trends, non small cell lung cancer, non-small cell lung cancer, opdivo, world conference on lung cancer
The global market value for non-small cell lung cancer treatment will rise from $6.9 billion in 2014 to $10.9 billion …
NICE recommends Keytruda for advanced skin cancer
September 7, 2015Research and Development, Sales and Marketing Merck, NICE, keytruda, skin cancer
NICE has approved Merck’s Keytruda (pembrolizumab) as a treatment for advanced skin cancer in final draft guidance for the NHS. …
Immatics and MD Anderson launch new company to develop ACR therapies
August 27, 2015Research and Development, Sales and Marketing Cancer, MD Anderson Cancer Center, immatics, keytruda
Immatics Biotechnologies and The University of Texas MD Anderson Cancer Center (MDACC) have together launched a new company focusing on …
Novartis and Merck skin cancer drugs move through pipeline
August 20, 2015Manufacturing and Production, Research and Development, Sales and Marketing Merck, Novartis, Odomzo, basal cell carcinoma, keytruda, melanoma, pembrolizumab, skin cancer, sonidegib
Both Novartis and Merck have hit regulatory milestones with their skin cancer drugs in the EU and the US. Novartis’ …
Merck in immuno-oncology collaboration with major cancer research centre
August 14, 2015Research and Development Cancer, Merck, keytruda, oncology
Merck is teaming up with the University of Texas to evaluate Merck’s anti-PD-1 therapy, Keytruda, in combination with other treatmentsA team …
BMS’ Opdivo accepted to UK early access scheme
June 30, 2015Sales and Marketing BMS, Cancer, NSCLC, eams, keytruda, opdivo
Bristol-Myers Squibb has scored another first with its new-generation oncology therapy Opdivo, which has become the first lung cancer drug …
Merck tests new Keytruda combination
June 3, 2015Research and Development, Sales and Marketing Merck, dynavax, keytruda
Merck is continuing to investigate Keytruda combinations as it signs a deal to test the drug with an immunotherapy from …
EMA recommends eight drugs for approval
May 22, 2015Sales and Marketing Amgen, BMS, EMA, Janssen, Merck, keytruda
The EMA has recommended eight medicines for approval in a round of reviews, including four new cancer indications. Amgen’s Repatha …
Merck to test Keytruda combinations
May 8, 2015Sales and Marketing BMS, Daiichi Sankyo, Merck, Plexxikon, keytruda, pembrolizumab
Merck will be teaming up with Daiichi Sankyo’s subsidiary Plexxikon to investigate immunotherapy combinations in cancer. A collaborative clinical trial …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
